Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Sarah C. Rutherford

Consulting or Advisory Role: Kite, a Gilead company, Dova Pharmaceuticals, ADC Therapeutics, Juno/Celgene, Karyopharm Therapeutics

Research Funding: Genentech (Inst), Karyopharm Therapeutics (Inst)

Jun Yin

Employment: Mayo Clinic

Mazyar Shadman

Consulting or Advisory Role: AbbVie, Genentech, AstraZeneca, Sound Biologics, Cellectar, Pharmacyclics, BeiGene, Bristol Myers Squibb/Celgene, MorphoSys, Innate Pharma, Kite, a Gilead company, Adaptive Biotechnologies, Epizyme, Fate therapeutics, Lilly, Regeneron, Adaptimmune, MustangBio, TG Therapeutics, MEI Pharma

Research Funding: Pharmacyclics (Inst), Acerta Pharma (Inst), Merck (Inst), TG Therapeutics (Inst), BeiGene (Inst), Celgene (Inst), Genentech (Inst), MustangBio (Inst), AbbVie (Inst), Sunesis Pharmaceuticals (Inst), Bristol Myers Squibb/Celgene

Michael L. LeBlanc

Consulting or Advisory Role: Agios

Vaishalee P. Kenkre

Research Funding: Novartis (Inst), MEI Pharma (Inst), Celgene/Bristol Myers Squibb (Inst), Seattle Genetics (Inst), Abbott Laboratories (Inst), Gilead Sciences (Inst)

Fangxin Hong

Employment: Pfizer

Consulting or Advisory Role: Merck Sharp & Dohme

Kristie A. Blum

Honoraria: American Society of Hemotology, Leidos Biomedical Research/NCI

Research Funding: Genentech/Roche (Inst), Seattle Genetics (Inst), BMSi (Inst)

Travel, Accommodations, Expenses: American Society of Hemotology

Peter Martin

Consulting or Advisory Role: Janssen, BeiGene, Karyopharm Therapeutics, Kite/Gilead, Verastem, ADC Therapeutics, Bristol Myers Squibb/Celgene, Epizyme, Merck, MorphoSys, Takeda

Research Funding: Karyopharm Therapeutics (Inst)

Sin-Ho Jung

Consulting or Advisory Role: Samsung

Cara Rosenbaum

Stock and Other Ownership Interests: Merck/Organon

Consulting or Advisory Role: Takeda, Janssen Biotech, Akcea Therapeutics, GlaxoSmithKline, Oncopeptides

Research Funding: Amgen, GlaxoSmithKline, Janssen Oncology, Karyopharm Therapeutics

Chaitra Ujjani

Honoraria: AstraZeneca, Pharmacyclics, Kite/Gilead, AbbVie, Genentech, MorphoSys, TG Therapeutics, Janssen, Incyte, BeiGene, Lilly

Consulting or Advisory Role: AstraZeneca, Epizyme, Atara Biotherapeutics

Research Funding: Pharmacyclics (Inst), AbbVie (Inst), Lilly, AstraZeneca/MedImmune, Adaptive Biotechnologies, Kite, a Gilead company

Paul M. Barr

This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Consulting or Advisory Role: Pharmacyclics, AbbVie, Seattle Genetics, Genentech, Novartis, Infinity Pharmaceuticals, Janssen, Merck, TG Therapeutics, MorphoSys, AstraZeneca, BeiGene, MEI Pharma, Bristol Myers Squibb/Celgene, Bayer

Research Funding: Pharmacyclics (Inst), AstraZeneca (Inst)

Bruce D. Cheson

Leadership: SymBio Pharmaceuticals

Consulting or Advisory Role: TG Therapeutics, AbbVie, Pharmacyclics/Janssen, Morphosys, Celgene, Karyopharm Therapeutics, Epizyme, Gilead Sciences, SymBio Pharmaceuticals, Parexel, Lilly, Imaging Endpoints

Speakers' Bureau: MorphoSys/Incyte, BeiGene, Lilly, TG Therapeutics

Research Funding: TG Therapeutics (Inst), Seattle Genetics (Inst), Bristol Myers Squibb (Inst), Gilead Sciences (Inst)

Travel, Accommodations, Expenses: SymBio Pharmaceuticals

Nancy L. Bartlett

Consulting or Advisory Role: Seattle Genetics, Roche/Genentech, ADC Therapeutics, BTG, Acerta Pharma

Research Funding: Seattle Genetics (Inst), Kite, a Gilead company (Inst), Merck (Inst), Bristol Myers Squibb (Inst), Celgene (Inst), Immune Design (Inst), Forty Seven (Inst), Janssen (Inst), Pharmacyclics (Inst), Millennium (Inst), ADC Therapeutics (Inst), Autolus (Inst), Roche/Genentech (Inst), Pfizer (Inst), Affimed Therapeutics (Inst)

Brad Kahl

This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Consulting or Advisory Role: Celgene, AbbVie, Pharmacyclics, Acerta Pharma, ADC Therapeutics, Genentech, Roche, AstraZeneca, BeiGene, Bayer, MEI Pharma, Kite/Gilead, MorphoSys, Janssen, Bristol Myers Squibb, Incyte, Genmab

Research Funding: Genentech (Inst), Acerta Pharma (Inst), ADC Therapeutics (Inst), Celgene (Inst)

Jonathan W. Friedberg

This author is the Editor-in-Chief of Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.

Research Funding: Enterome (Inst)

Patents, Royalties, Other Intellectual Property: Patient on bone marrow microenvironment signals

Sumithra J. Mandrekar

Honoraria: BeiGene

Consulting or Advisory Role: Flatiron Health, Harbinger Oncology, Inc

Other Relationship: Beigene

John P. Leonard

Consulting or Advisory Role: Celgene, Bristol Myers Squibb, Gilead Sciences, Epizyme, Bayer, Genentech/Roche, ADC Therapeutics, MEI Pharma, AstraZeneca, Merck, Morphosys, Karyopharm Therapeutics, Sutro Biopharma, Miltenyi Biotec, Regeneron, Akcea Therapeutics, Sandoz, Nordic Nanovector, Genmab, AbbVie, Incyte, Janssen Oncology, Eisai, MustangBio, Second Genome

Research Funding: Celgene (Inst), Alliance for Clinical Trials in Oncology (Inst), Takeda (Inst), Pfizer (Inst), National Cancer Institute (Inst), Janssen Oncology (Inst), Epizyme (Inst), Genentech (Inst)

Travel, Accommodations, Expenses: BeiGene

No other potential conflicts of interest were reported.